| abstract |
anti-cd40 antibody, antigen-binding fragment and pharmaceutical use thereof. the present invention relates to an anti-cd40 antibody, an antigen-binding fragment and a pharmaceutical use thereof. the heavy chain constant regions of the anti-cd40 antibody and the antigen-binding fragment thereof contain mutations. due to the mutations, the anti-cd40 antibody loses binding activity to fcriii and binding of anti-cd40 antibody and fcriib is increased, thus losing antibody-dependent cytotoxicity (adcc), but improving fcriib-mediated antibody cross-linking. mutations in heavy chain constant regions increase cd40 activation, and increase dendritic cell presentation to antigens. the anti-cd40 antibody and antigen-binding fragment thereof can be used as anti-cancer drugs to treat diseases or symptoms mediated by cd40. |